
|Articles|March 1, 2007
iCo IND accepted
The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007.
Advertisement
The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007, a treatment for diabetic macular oedema (DME).
iCo-007 is a second generation antisense compound that targets c-Raf kinase messenger RNA and reduces the oedema by decreasing the signalling of growth factors such as VEGF that signal through the c-Raf kinase pathway.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
2
FLORetina 2025: New horizons in research and risk management for ROP
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
5













































